Immunologic effects of dioxin: new results from Seveso and comparison with other studies.

Animal studies indicate that the immune system is one of the most sensitive targets of the toxic effects of 2,3,7,8-tetrachloro-p-dibenzodioxin (TCDD). TCDD inhibits immunoglobulin secretion and decreases resistance to bacterial, viral, and parasitic infections in exposed animals. Nearly 20 years after the Seveso, Italy, accident, we measured immunoglobulin and complement plasma levels in a random sample of the population in the most highly exposed zones (n = 62) and in the surrounding noncontaminated area (n = 58). Plasma IgG levels decreased with increasing TCDD plasma concentration (r = -0.35, p = 0.0002). Median IgG concentration decreased from 1,526 mg/dL in the group with the lowest (< 3.5 ppt) TCDD levels to 1,163 mg/dL in the group with the highest (20.1-89.9 ppt) TCDD levels (p = 0.002). The association was significant (p = 0.0004) after adjusting for age, sex, smoking, and consumption of domestic livestock and poultry in multiple regression analysis and persisted after exclusion of subjects with inflammatory diseases and those using antibiotics or nonsteroidal anti-inflammatory drugs. IgM, IgA, C3, and C4 plasma concentrations did not exhibit any consistent association with TCDD levels. We performed a systematic review of all the articles published between 1966 and 2001 on human subjects exposed to TCDD reporting information on circulating levels of immunoglobulins and/or complement components. The literature indicates that the evidence for effects of TCDD on humoral immunity is sparse. Methodologic issues, results, and possible sources of variation between studies are discussed. The possible long-term immunologic effects of TCDD exhibited by the participants of the present study, coupled with the increased incidence of lymphatic tumors in the area of the accident, warrant further investigation. Key words: complement, dioxin, environmental disasters, immune system, immunoglobulins, tetrachlorodibenzodioxin. Environ Health Perspect 110:1169-1173 (2002). [Online 27 September 2002]

http://ehpnet1.niehs.nih.gov/docs/2002/110p1169-1173baccarelli /abstract.html

**********

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCCD) has a long biological half-life in humans (> 7 years) and induces carcinogenicity and severe developmental, endocrinologic, immunologic, and reproductive toxicity in animal experiments (Birnbaum and Tuomisto 2000; Dragan and Schrenk 2000; IARC 1997). The immune system is one of its most sensitive targets (Birnbaum and Tuomisto 2000). TCDD inhibits immunoglobulin secretion and decreases resistance to bacterial, viral, and parasitic infections in exposed animals (Birnbaum and Tuomisto 2000; Holsapple et al. 1991; Nohara et al. 2002). In humans, increased incidence of and mortality from lymphatic tumors have been found in exposed subjects, even though there is a lack of consistency among studies (Bertazzi et al. 2001; IARC 1997). Previous investigations have shown alterations in humoral immunity, but with no consistent dose-response relationship and often with poor control for confounders (Neubert et al. 2000).

In 1976 an industrial accident contaminated a residential area surrounding Seveso, Italy, with high levels of TCDD. The exposure was acute, relatively pure, and affected more than 45,000 men, women, and children. Measurements of soil levels of TCDD within 5 weeks delimited three zones (A, B, and R) of decreasing contamination (Bertazzi and Di Domenico 1994). Twenty years after the exposure, TCDD levels were still high in exposed persons, particularly in women. Plasma TCDD ranged between 9.8 and 89.9 ppt in individuals from zone A, 1.0-62.6 ppt in individuals from zone B, and 1.0-18.1 ppt in individuals from the noncontaminated surrounding area (non-ABR) (Landi et al. 1997, 1998).

In the present article we report on plasma immunologic parameters measured about 20 years after the accident in a random sample of the population of the area. Previous human studies investigating the effects of TCDD on humoral immunity are also discussed.

Materials and Methods

Study subjects and laboratory methods. The selection of subjects, their recruitment, and their characteristics, as well as dioxin assay methods, have been described elsewhere (Landi et al. 1997, 1998). Briefly, we randomly sampled 62 subjects from the most highly contaminated zones (A and B) and 59 subjects from the surrounding noncontaminated area (non-ABR zone). Study subjects were frequency matched by sex, decade of age, and cigarette smoking status. Residence in the specific zone was verified at recruitment. We obtained approvals of the institutional review boards and written informed consent from each study subject. A structured questionnaire, which included the collection of a detailed personal medical history and medication use in the week before the study, was administered to all subjects through personal interview.

We determined internal dose of TCDD using high-resolution mass spectrometric analysis performed on human plasma, as described by Patterson et al. (1987). Eleven subjects (4 from zone B and 7 from zone non-ABR) were excluded from the analyses based on blood TCDD because of missing data. Standard clinical hematologic and chemistry assays were performed. We quantified plasma immunoglobulins IgA, IgG, and IgM, and complement components C3 and C4 using common nephelometric methods (Thomas 1990). We used plasma protein electrophoresis to exclude monoclonal immunoglobulins. One subject from zone non-ABR was excluded from the study because of missing immunologic evaluation. We performed all assays blinded to subject's exposure status.

Statistical methods. We used nonparametric tests (Wilcoxon rank-sum, Kruskal-Wallis) for group comparisons. We performed simple and multiple regression analyses to assess correlations between variables. Several variables, such as age, sex, smoking status, body mass index, consumption of domestic livestock and poultry, alcohol consumption, acute and chronic medical conditions, and current medication use were possible confounding factors. The variables adjusted for in multiple regression models were selected on the basis of their correlation with TCDD and the immunologic parameters of interest in univariate analysis. All analyses were performed using the Stata statistical package, Release 7.0 (Stata Corporation, College Station, TX, USA).

Literature search. To document any published association between TCDD and immunologic parameters, in February 2002 we performed a PubMed (National Library of Medicine, Bethesda, MD, USA) search of all studies published from 1966 through December 2001. The main features of the studies and results are summarized in Table 1. We used the search query ["immune system," "immunity," "allergy and immunology," "immunocompetence," "immunologic," "immunoglobulins," "gamma globulins," "antibody formation," "IgA," "IgM," "IgG," "complement," "C3," OR "C4,"] AND ["TCDD," "tetrachlorodibenzodioxin," OR "dioxins"]. All citations and online abstracts were examined. We reviewed all the studies on human subjects exposed to TCDD reporting information on circulating levels of IgG, IgM, IgA, and/or complement components. Studies on subjects exposed to organochlorine compounds that did not include TCDD were not considered. Details on number of exposed and nonexposed (control) subjects, sex and mean age of study subjects, characteristics of the exposure, time from the exposure, final results, and control for confounders were retrieved for each study. When the mean age of all study subjects was not reported, we computed it using individual age data, if available. Most articles specified the year of the beginning (YBE) and of the end (YEE) of the exposure, and the year of the beginning (YBR) and of the end (YER) of subjects' recruitment. If the time range from the first exposure to the enrollment in the study was not specified in the article, we derived it as lower limit = YBR - YEE; upper limit = YER - YBE. When multiple methods of exposure assessment were featured in a single study, we reported only that used in the statistical analysis of immunologic parameters. Study design and statistical methods were reviewed, and the methods for confounding prevention or control, such as matching, restriction, and multivariable regression analysis (Rothman and Greenland 1998) were ascertained. Immunologic parameters were considered associated with TCDD exposure when statistically significant results (p < 0.05) were reported.

Results

We found a significant decrease in IgG levels (Figure 1) in the exposed subjects. Plasma IgG ranged from 2,252 to 809 mg/dL and progressively decreased with increasing lipid-adjusted TCDD plasma concentration (r = -0.35, p = 0.0002). The finding was slightly more pronounced in female (n = 53, r = -0.39, p = 0.003) than in male subjects (n = 56, r = -0.33, p = 0.02). When individuals were divided in categories of internal dose according to TCDD quintiles (Table 2), median IgG concentration decreased from 1,526 mg/dL in the group with the lowest (<3.5 ppt) TCDD levels to 1,163 mg/dL in the group with the highest (20.1-89.9 ppt) TCDD levels (test for difference between groups, p = 0.002).

[FIGURE 1 OMITTED]

Consistently, subjects from the most contaminated zones had lower IgG than subjects from the surrounding noncontaminated area. Median IgG levels were 1,403 mg/dL in the noncontaminated area (non-ABR, n = 58), 1,294 mg/dL in zone B (n = 55; p = 0.03 vs. non-ABR), and 1,142 mg/dL in zone A, the most contaminated area (n = 7; p = 0.01 vs. non-ABR).

We considered several factors that may have biased the results. We previously showed that in this population smoking and consumption of domestic livestock and poultry were among the major determinants of high TCDD plasma levels, together with female gender and older age (Landi et al. 1998). In the present study, median IgG levels were lower in current (1,202 mg/dL, n = 22) and former (1,281 mg/dL, n = 28) smokers, as compared with nonsmokers (1,424 mg/dL, n = 59; p = 0.03, test for difference between groups). Subjects who reported consumption of domestic livestock at the time of the accident (n = 34) had lower levels of IgG than those who did not report such consumption (1,228 vs. 1,417 mg/dL, p = 0.06). We used multivariable regression models to control for these possible confounding factors. After adjusting for age, sex, smoking, and consumption of domestic livestock, the inverse association between plasma TCDD and IgG remained highly significant (p = 0.0004). The results did not change after exclusion of an outlier subject who exhibited the lowest IgG levels (r = -0.32, p = 0.0008 in simple regression analysis, and p = 0.002 after adjusting for age, sex, smoking, and consumption of domestic livestock). Based on clinical chemistry assays and plasma protein electrophoresis, no subjects had monoclonal gammopathy, and four had increased C-reactive protein. No subjects reported treatment with immunosuppressive drugs, and five subjects had used antibiotics in the week before the study. An additional 22 individuals had taken aspirin or other nonsteroidal anti-inflammatory agents, mostly for headache, osteoarthritis, or menstrual pain. We repeated all statistical analyses excluding each or all the groups (involving a total of 28 subjects) mentioned above and did not find any substantial difference in the results (data not shown).

IgM, IgA, and complement component C3 plasma concentrations were not significantly associated with TCDD levels (Table 2). Complement component C4 concentrations were higher in the highest TCDD group (Table 2) and a positive trend was found in regression analysis (r = 0.21; p = 0.03). This association was not significant after adjusting in multivariable regression analysis for age (p = 0.29), or for age, sex, smoking, and consumption of domestic livestock (p = 0.11).

Overall, we retrieved 13 articles that reported results on immunoglobulin and complement levels in TCDD-exposed subjects (Table 1). Twelve studies measured immunoglobulins of one or more immunoglobulin classes. One article reported total [gamma]-globulin levels (Jansing and Korff 1994). Four studies described a decrease in immunoglobulin levels (Halperin et al. 1998; Jansing and Korff 1994; Lovik et al. 1996; Neubert et al. 2000), and two studies reported increased IgG (Ott et al. 1994; Webb et al. 1989). Complement levels were determined in three studies, and only one of them included both C3 and C4 (Ott et al. 1994). C4 levels, but not C3, were positively associated with blood TCDD in this study. Increased total hemolytic complement activity (CH50) was described in children examined immediately after the Seveso accident (Pocchiari et al. 1979; Sirchia 1982). Halperin et al. (1998) reported increased C3 concentrations in the exposed subjects but no dose-response relationship with serum TCDD.

Five of the studies reported in Table 1 included subjects exposed not only to TCDD but also to other polychlorinated dibenzodioxins (PCDDs), polychlorinated dibenzofurans (PCDFs), and, in some instances, to polycyclic chlorinated hydrocarbons (PAHs) and heavy metals. In other studies carried out in occupational settings, the presence of exposure to other chemicals cannot be ruled out. The sample size was generally small, with the exception of two investigations, which included more than 500 subjects (Halperin et al. 1998; Michalek et al. 1999). Most studies were restricted to males or to a specific age or were based on a matched design between exposed and nonexposed subjects. These methods allow for the control of a limited number of confounding variables. Five studies used multivariable statistical models (Halperin et al. 1998; Jung et al. 1998; Michalek et al. 1999; Neubert et al. 2000; Ott et al. 1994), but not all the potential confounders were considered in most of them.

Discussion

Nearly 20 years after the Seveso accident, we found a suppression of IgG plasma levels in subjects exposed to TCDD.

Numerous experimental studies showed that TCDD may suppress both humoral and cell-mediated immune responses (Birnbaum and Tuomisto 2000; Kerkvliet 2002). Inhibition of immunoglobulin secretion has been demonstrated in multiple animal species (Birnbaum and Tuomisto 2000; Nohara et al. 2002; Vorderstrasse et al. 2001), as well as in human lymphocytes cultivated in vitro (Sulentic et al. 2000). Zober et al. (1994) found an increased incidence of infectious and parasitic diseases in a small retrospective cohort study of TCDD-exposed workers, but clinical diagnoses were ill-defined.

The literature indicates that evidence for TCDD effects on humoral immunity is sparse. We reviewed all the articles published between 1966 and 2001 on subjects exposed to TCDD reporting information on circulating levels of IgG, IgM, IgA, and/or complement components (Table 1). Similarly to our findings, Neubert et al. (2000) reported a decrease in IgG levels, mainly of the Ig[G.sub.1] subclass, the most prevalent of human IgG molecules, in workers exposed to PCDDs and PCDFs in Germany (Table 1, trial 1). It is suggestive that the subjects enrolled in this study had blood TCDD levels similar to those observed in our study. However, no association was found between Ig[G.sub.1] and blood toxic equivalent levels when these results were pooled with a second group of workers predominantly exposed in a metal recycling plant to penta- and hexachlorinated dibenzofurans, as well as to heavy metals, such as lead and cadmium (trial I + II). Halperin et al. (1998) showed lower mean IgG levels in 259 male subjects who reported exposure to TCDD during the manufacturing of 2,4,5-trichlorophenate as compared to neighborhood referents. Serum TCDD was measured in all exposed workers and in only 79 of the 243 control subjects (TCDD levels were < 20 ppt in this subsample of control subjects). When TCDD serum levels were considered, IgG did not exhibit any consistent trend in a multivariable model including age, smoking status, and alcohol consumption. Two additional small studies, which did not include IgG measurement, found a decrease in total [gamma]-globulin (Jansing and Korff 1994) and serum IgM (Lovik et al. 1996).

In Seveso, an earlier study conducted on 44 children (3-7 years of age, 20 of whom had chloracne) shortly after the accident exhibited no change in immunoglobulin concentrations (Pocchiari et al. 1979). Other reports showed no alterations in immunoglobulin levels (Hoffman et al. 1986; Jennings et al. 1988; Jung et al. 1998; Marth et al. 1995; Michalek et al. 1999; Nagayama et al. 2001). A slight positive increase in IgG levels was found in two studies (Ott et al. 1994; Webb et al. 1989). However, these studies did not exclude subjects with concurrent medical conditions likely to increase circulating IgG levels (Ravel 1995). In one of the two investigations, the authors reported the presence of a subject affected by liver cancer who had the highest concentration of TCDD and very high IgG (Ott et al. 1994). This subject possibly acted as an outlier in the regression analysis. In the same study, another subject had liver cirrhosis. In the second investigation (Webb et al. 1989), 1 of the 12 subjects with high TCDD levels had hepatomegaly.

As for the complement components, one investigation showed a positive association between blood TCDD and C4 (Ott et al. 1994). Increases in C3 (Halperin et al. 1998) and in CH50 (Sirchia 1982) have been also reported elsewhere. Similarly, we found a weak positive association between C4 and TCDD plasma levels, but the association was not significant after adjusting for age and for other potential confounding factors.

Differences in subject characteristics, time frame of the studies, as well as in levels, nature, modality, and assessment of the exposure, may account for the conflicting results (Table 1) and certainly limit between-studies comparisons, also hindered by the dissimilar and, in some instances, incomplete presentations of the results. Our study was conducted on subjects of both sexes and within a wide age range, who had been acutely exposed to TCDD. In contrast, most other studies, including the largest investigation (Michalek et al. 1999) with 894 U.S. Vietnam veterans exposed to Agent Orange and 1,167 unexposed individuals, which showed no change in immunoglobulin levels, comprised mostly males, with long-term exposure often to multiple chemical agents, in occupational (or military) settings. Due to the type of selection, most subjects were likely young and/or healthy, and thus not representative of the general population (Li and Sung 1999). In the great majority of the investigations, the small number of subjects limited the power to detect alterations of the immunologic parameters.

In earlier studies, the measurement of the internal dose of TCDD and of other dioxin-like compounds was estimated by using surrogate measures, such as residence or presence in the contaminated facilities. Kerkvliet (1995) speculated that subjects with little or no exposure to TCDD might have also been included in these studies, accounting for the lack of significant findings. In our study, results based on TCDD plasma levels did not differ from the results based on subjects' residence in the exposed areas, but the measurement of individual plasma TCDD levels allowed for a more refined dose-response assessment.

Recently, Neubert et al. (2000) indicated various factors that can influence immunologic variables and suggested that conclusions on possible effects of exogenous agents may be drawn only when all known confounders are taken into account. The authors provided a list of possible confounders that included age, body mass, smoking, alcohol consumption, acute and chronic diseases, and use of medications. We controlled for all these factors in our analyses, in contrast to many investigations listed in Table 2.

The present study was based on a relatively small random sample of the resident population of the territory contaminated with TCDD after the Seveso accident. A similar number of subjects was drawn from the population of the surrounding noncontaminated area, which shares the same environmental, social, educational, and occupational characteristics. A detailed assessment of personal medical history and medication use was performed and compared with the results of a selection of standard laboratory tests.

The clinical significance of our finding is uncertain. The protective capacity of circulating IgG antibodies against microbial challenge is well documented (Heinzel 2000). Children and adult subjects with B-cell-related primary immunodeficiency syndromes, which exhibit reduced circulating immunoglobulins, are prone to recurrent infections and allergic diseases (Heinzel 2000). These subjects are at very high risk for non-Hodgkin lymphoma (Ziegler 1994) and increased occurrence of non-Hodgkin lymphoma has been also reported in TCDD-exposed subjects (IARC 1997). However, IgG levels found in our study sample are far above those typically observed in patients with antibody immunodeficiency disorders ([less than or equal to] 350 mg/dL) (Heinzel 2000) and only one study subject had plasma IgG levels below the lower reference value (< 878 mg/dL) adopted by the clinical laboratory of the hospital.

Our finding may reflect a broader alteration of the immune system that more sensitive markers could reveal. Lymphocyte phenotypic subsets, proliferative responses to mitogens, and basal and stimulated in vitro cytokine production (Colosio et al. 1999) could be assessed in future studies. In addition, genetic aberrations associated with lymphohemopoietic neoplasms (Basecke et al. 2002) could be tested. The results of such studies might have broad implications for public health, as current background levels of human exposure to dioxin-like compounds are close to the recently established tolerable daily intake (WHO-ECEH 2000) and thus might be sufficient to elicit toxic effects on the immune system.

In conclusion, our study showed a strong inverse relationship between plasma IgG and increasing TCDD levels. Plasma TCDD was not correlated with IgM, IgA, C3, or C4 levels. The possible long-term immunologic effects of TCDD, coupled with the increased incidence of lymphatic tumors in the area of the accident (Bertazzi et al. 2001) and the conflicting results in the literature warrant further investigation.

Table 1. Exposure to 2,3,7,8-tetraclorodibenzo-p-dioxin and levels
of immunoglobulins and complement components in human subjects. Main
features and results of the studies published between 1966 and
December 2001.

        Study                                  Subjects

                                No.                              Mean
                                ex-        No.                   age
Reference    Setting           posed     controls      Sex     (years)

Pocchiari    Seveso, Italy       45       45 (b)      M + F    3-7 (c)
et al.
1979

Hoffman et   Quail Run          129      139          M + F    27.5
al. 1986     Park, Missouri,
             USA

Jennings     Coalite             18       15          M + F    49.8
et al.       Ltd, UK
1988

Webb et      Missouri, USA       40       --          M + F    45.1
al. 1989

Jansing      Trichlorophenol      8       --            NR     49.6
and Korff    plant, Germany
1994

Ott et       BASF AG,           132      196/42 (f)     M      60.7 (g)
al. 1994     Germany            132       --            M      60.7

Marth et     Garbage dumps,     100       98            M      10
al. 1995     Egypt

Lovik et     Frierfjord,         24       --            M      46 (h)
al. 1996     Norway

Halperin     NIOSH study        259      243            M      55.7
et al.       subgroup
1998

Jung et      Pesticide          187       --          Mainly   56.0 (h)
al. 1998     factory,                                   M
             Germany

Michalek     U.S. Vietnam       894    1,167            M      53.8
et al.       Veterans
1999

Neubert et   Boehringer,         88       --          Mainly   36.5
al. 2000     Germany                                    M
             (trial I)

             Rastatt,            70       --          Mainly   51.5
             Germany                                    M
             (trial II)

             Trial I +          158       --          Mainly   43.1
             trial II                                   M

Nagayama     Yusho poisoning     69       --          M + F    63.4
et al.
2001

        Study                                 Exposure

                                                           Years from
                                                              first
                                              Acute vs.     exposure
Reference    Setting           Toxicants       chronic    to the study

Pocchiari    Seveso, Italy     TCDD             Acute     [less than or
et al.                                                    equal to] 1.5
1979

Hoffman et   Quail Run         TCDD            Chronic        1-14
al. 1986     Park, Missouri,
             USA

Jennings     Coalite           TCDD             Acute          17
et al.       Ltd, UK
1988

Webb et      Missouri, USA     TCDD            Chronic         NR
al. 1989

Jansing      Trichlorophenol   TCDD            Chronic        15-28
and Korff    plant, Germany
1994

Ott et       BASF AG,          TCDD             Acute         20-39
al. 1994     Germany           TCDD             Acute         20-39

Marth et     Garbage dumps,    PCDDs/PCDFs,    Chronic         NR
al. 1995     Egypt             PAHs, heavy
                               metals

Lovik et     Frierfjord,       PCDDs/PCDFs     Chronic         NR
al. 1996     Norway

Halperin     NIOSH study       TCDD            Chronic        15-37
et al.       subgroup
1998

Jung et      Pesticide         PCDDs/PCDFs     Chronic        > 10
al. 1998     factory,
             Germany

Michalek     U.S. Vietnam      TCDD            Chronic        16-30
et al.       Veterans
1999

Neubert et   Boehringer,       PCDDs/PCDFs      Acute          NR
al. 2000     Germany
             (trial I)

             Rastatt,          PCDFs/PCDDs,    Chronic        > 10
             Germany           lead,
             (trial II)        cadmium

             Trial I +         PCDDs/PCDFs,     Acute        NR for
             trial II          lead               +          trial I
                               cadmium         chronic

Nagayama     Yusho poisoning   PCDFs,           Acute          29
et al.                         PCBs,
2001                           PCDDs

        Study                              Exposure

                                                        TCDD
Reference    Setting           Assessment           internal dose

Pocchiari    Seveso, Italy     Residence,               N/A
et al.                         chloracne
1979

Hoffman et   Quail Run         Residence                N/A
al. 1986     Park, Missouri,   history
             USA

Jennings     Coalite           Presence at              N/A
et al.       Ltd, UK           the accident/
1988                           clean-up

Webb et      Missouri, USA     Adipose               ND-750 ppt
al. 1989                       tissue TCDD

Jansing      Trichlorophenol   Blood TCDD          163-1,935 ppt
and Korff    plant, Germany
1994

Ott et       BASF AG,          Work history        1-553 ppt  (g)
al. 1994     Germany           Blood TCDD            1-553 ppt

Marth et     Garbage dumps,    Residence                 NR
al. 1995     Egypt

Lovik et     Frierfjord,       Blood                     NR
al. 1996     Norway            PCDDs/PCDFs

Halperin     NIOSH study       Work history (j)   ND-3,389 ppt (k)
et al.       subgroup
1998

Jung et      Pesticide         Blood, serum,        1.2-893 ppt
al. 1998     factory,          or adipose
             Germany           tissue TCDD

Michalek     U.S. Vietnam      Blood TCDD            0-618 ppt
et al.       Veterans
1999

Neubert et   Boehringer,       Blood                 1-140 ppt
al. 2000     Germany           PCDDs/PCDFs
             (trial I)

             Rastatt,          Blood                  2-17 ppt
             Germany           PCDDs/PCDFs
             (trial II)

             Trial I +         Blood                 1-140 ppt
             trial II          PCDDs/PCDFs

Nagayama     Yusho poisoning   Blood                   NR (n)
et al.                         PCDDs/PCDFs,PCBs
2001

        Study                                 Results

Reference    Setting                  IgG                IgM

Pocchiari    Seveso, Italy       [right arrow]      [right arrow]
et al.
1979

Hoffman et   Quail Run           [right arrow]           N/A
al. 1986     Park, Missouri,
             USA

Jennings     Coalite             [right arrow]      [right arrow]
et al.       Ltd, UK
1988

Webb et      Missouri, USA        [up arrow]        [right arrow]
al. 1989

Jansing      Trichlorophenol          [gamma]-Globulins (e)
and Korff    plant, Germany
1994

Ott et       BASF AG,            [right arrow]      [right arrow]
al. 1994     Germany              [up arrow]        [right arrow]

Marth et     Garbage dumps,      [right arrow]           N/A
al. 1995     Egypt

Lovik et     Frierfjord,              N/A          [down arrow] (i)
al. 1996     Norway

Halperin     NIOSH study       [down arrow] (j)     [right arrow]
et al.       subgroup
1998

Jung et      Pesticide           [right arrow]      [right arrow]
al. 1998     factory,
             Germany

Michalek     U.S. Vietnam        [right arrow]      [right arrow]
et al.       Veterans
1999

Neubert et   Boehringer,       [down arrow] (l)     [right arrow]
al. 2000     Germany
             (trial I)

             Rastatt,            [right arrow]      [right arrow]
             Germany
             (trial II)

             Trial I +         [right arrow] (m)    [right arrow]
             trial II

Nagayama     Yusho poisoning     [right arrow]      [right arrow]
et al.
2001

        Study                              Results

Reference    Setting                IgA              C3

Pocchiari    Seveso, Italy     [right arrow]      N/A (d)
et al.
1979

Hoffman et   Quail Run              N/A             N/A
al. 1986     Park, Missouri,                        N/A
             USA

Jennings     Coalite           [right arrow]        N/A
et al.       Ltd, UK
1988

Webb et      Missouri, USA     [right arrow]        N/A
al. 1989

Jansing      Trichlorophenol     [gamma]-           N/A
and Korff    plant, Germany    Globulins (e)
1994

Ott et       BASF AG,          [right arrow]   [right arrow]
al. 1994     Germany            [up arrow]     [right arrow]

Marth et     Garbage dumps,    [right arrow]        N/A
al. 1995     Egypt

Lovik et     Frierfjord,            N/A             N/A
al. 1996     Norway

Halperin     NIOSH study       [right arrow]   [up arrow] (j)
et al.       subgroup
1998

Jung et      Pesticide         [right arrow]        N/A
al. 1998     factory,
             Germany

Michalek     U.S. Vietnam      [right arrow]        N/A
et al.       Veterans
1999

Neubert et   Boehringer,       [right arrow]        N/A
al. 2000     Germany
             (trial I)

             Rastatt,          [right arrow]        N/A
             Germany
             (trial II)

             Trial I +         [right arrow]        N/A
             trial II

Nagayama     Yusho poisoning   [right arrow]        N/A
et al.
2001

        Study                           Results

                                               Control for
Reference    Setting                C4         confounders (a)

Pocchiari    Seveso, Italy        N/A (d)      No
et al.
1979

Hoffman et   Quail Run              N/A        Age, sex, socio-
al. 1986     Park, Missouri,        N/A        economic level
             USA

Jennings     Coalite                N/A        Age, sex, body
et al.       Ltd, UK                           weight, social
1988                                           class, alcohol,
                                               smoking

Webb et      Missouri, USA          N/A        Age, sex
al. 1989

Jansing      Trichlorophenol        N/A        No
and Korff    plant, Germany
1994

Ott et       BASF AG,          [right arrow]   Sex
al. 1994     Germany            [up arrow]     Age, sex, body
                                               mass index,
                                               smoking

Marth et     Garbage dumps,         N/A        Age, sex
al. 1995     Egypt

Lovik et     Frierfjord,            N/A        Sex
al. 1996     Norway

Halperin     NIOSH study            N/A        Age, race, sex
et al.       subgroup
1998

Jung et      Pesticide              N/A        Age, smoking
al. 1998     factory,
             Germany

Michalek     U.S. Vietnam           N/A        Age, sex, % body
et al.       Veterans                          fat, race, military
1999                                           occupation,
                                               alcohol, smoking

Neubert et   Boehringer,            N/A        No
al. 2000     Germany
             (trial I)

             Rastatt,               N/A        No
             Germany
             (trial II)

             Trial I +              N/A        Age, smoking, ESR,
             trial II                          lymphoocytes/
                                               [micro]L

Nagayama     Yusho poisoning        N/A        No
et al.
2001

Abbreviations: ESR, erythrocyte sedimentation rate; F, female; M,
male; N/A, not available; ND, nondetectable; NR, not reported; PAHs,
polycyclic chlorinated hydrocarbons; PCBs, polychlorinated biphenyls;
PCDDs, polychlorinated dibenzo-p-dioxins; PCDFs, polychlorinated
dibenzofurans; [up arrow], positive association; [down arrow],
negative association; [right arrow], no significant association with
the exposure.

(a) Most studies were restricted to males or to a specific age or were
based on a matched design between exposed and nonexposed subjects; few
studies used multivariable statistical models. (b) Number of controls
not specified in the article, which summarized the results of
periodical assessments of immunologic parameters; according to a
later report by Sirchia (1982), control groups varied at each
assessment (average sample size = 45). (c) Age range. (d) In the same
study, an increase in total hemolytic complement activity (CH50) was
reported by Sirchia (1982). (e) Negative association between total
[gamma]-globulin concentrations and TCDD blood levels (Spearman
rank-correlation: [r.sub.s] = -0.71, p = 0.047, calculated from data
reported in the paper). (f) Immunoglobulin data from a convenience
sample of 196 subjects were provided for comparison; a different
referent sample (n = 42) was used for C3 and C4 results. (g) Mean age
and TCDD levels of exposed subjects; blood TCDD was not assayed in
controls. (h) Median age. (i) Results not shown, but only summarized
in the paper; statistical significance was not reported. (j) Immune
parameters not consistently related to TCDD serum levels after
adjusting for age, alcohol, and smoking. (k) Serum TCDD measured
in exposed workers and in 79 control subjects (< 20 ppt in controls).
(l) Negative association with IgG and IgG1 levels. (m) Only results
on IgG1 reported. (n) Study subjects were divided in three exposure
groups according to the following TCDD toxic equivalent levels: < 70
ppt, 70-200 ppt, [greater than or equal to] 200 ppt.

Table 2. Subjects' plasma immunoglobulins and complement
components by TCDD plasma levels in Seveso, Italy.

                              Plasma TCDD (a)

               1.2-3.5 ppt (n = 21)     3.6-6.0 ppt (n = 21)

                       Interquartile            Interquartile
              Median     range (b)     Median     range (b)

IgG (mg/dL)    1,526    1,388-1,725     1,422    1,121-1,566
IgM (mg/dL)      168      126-188         134      107-183
IgA (mg/dL)      230      191-308         213      157-300
C3 (mg/dL)        76       67-85           69       61-78
C4 (mg/dL)        25       20-31           28       21-32

                              Plasma TCDD (a)

              6.1-9.3 ppt (n = 23)     9.4-20.0 ppt (n = 22)

                       Interquartile            Interquartile
              Median     range (b)     Median     range (b)

IgG (mg/dL)    1,363    1,294-1,575     1,302    1,168-1,538
IgM (mg/dL)      164       92-265         173      112-233
IgA (mg/dL)      269      201-325         223      193-310
C3 (mg/dL)        71       63-78           75       64-86
C4 (mg/dL)        26       22-33           26       20-33

                 Plasma TCDD (a)

              20.1-89.9 ppt (n = 22)

                       Interquartile
              Median     range (b)     p-Value (c)

IgG (mg/dL)    1,163    1,122-1,316       0.002
IgM (mg/dL)      135       86-165         0.42
IgA (mg/dL)      301      167-354         0.66
C3 (mg/dL)        76       61-87          0.64
C4 (mg/dL)        33       26-38          0.04

(a) Plasma TCDD quintiles were used to define TCDD categories.
(b) 25th-75th percentiles. (c) Kruskal-Wallis test for differences
between TCDD categories.

REFERENCES

Basecke J, Griesinger F, Trumper L, Brittinger G. 2002 Leukemia- and lymphoma-associated genetic aberrations in healthy individuals. Ann Hematol 81:64-75.

Bertazzi PA. Consonni D, Bachetti S, Rubagotti M, Baccarelli A, Zocchetti C, et al. 2001. Health effects of dioxin exposure: a 20-year mortality study. Am J Epidemiol 153:1031-1044.

Bertazzi PA, Di Domenico A. 1994. Chemical, environmental, and health aspects of the Seveso, Italy accident. In: Dioxins and Health (Schecter A, ed). New York: Plenum Press, 587-632.

Birnbaum LS, Tuomisto J. 2000. Non-carcinogenic effects of TCDD in animals. Food Addit Contam 17:275-288.

Colosio C, Corsini E, Barcellini W, Maroni M. 1999. Immune parameters in biological monitoring of pesticide exposure: current knowledge and perspectives. Toxicol Lett 108:285-295.

Dragan YP, Schrenk D. 2000. Animal studies addressing the carcinogenicity of TCDD (or related compounds) with an emphasis on tumour promotion. Food Addit Contam 17:289-302.

Halperin W, Vogt R, Sweeney MH, Shopp G, Fingerhut M, Petersen M. 1998. Immunological markers among workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Occup Environ Med 55:742-749.

Heinzel FP. 2000. Antibodies. In: Principles and Practice of Infectious Diseases (Mandell GL, Bennett JE, Dolin R, eds). 5th ed. Philadelphia: Churchill Livingstone, 45-67.

Hoffman RE, Stehr-Green PA, Webb KB, Evans RG, Knutsen AP, Schramm WF, et al. 1986. Health effects of long-term exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. JAMA 255:2031-2038.

Holsapple MP, Snyder NK, Wood SC, Morris DL. 1991. A review of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced changes in immunocompetence: 1991 update. Toxicology 69:219-255.

IARC. 1997. Polychlorinated Dibenzo-para-Dioxins and Polychlorinated Dibenzofurans. IARC Monogr Eval Carcinog Risks Hum 69.

Jansing PJ, Korff R. 1994. Blood levels of 2,3,7,8-tetrachlorodibenzo-p-dioxin and gamma-globulins in a follow-up investigation of employees with chloracne. J Dermatol Sci 8:91-95.

Jennings AM, Wild G, Ward JD, Ward AM. 1988. Immunological abnormalities 17 years after accidental exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Br J Ind Med 45:701-704.

Jung D, Berg PA, Edler L, Ehrenthal W, Fenner D, Flesch-Janys D, et al. 1998: Immunologic findings in workers formerly exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin and its congeners. Environ Health Perspect 106(suppl 2):689-695.

Kerkvliet NI. 1995. Immunological effects of chlorinated dibenzo-p-dioxins. Environ Health Perspect 103 (suppl 9):47-53.

--. 2002. Recent advances in understanding the mechanisms of TCDD immunotoxicity. Int Immunopharmacol 2:277-291.

Landi MT, Consonni D, Patterson DG Jr, Needham LL, Lucier G, Brambilla P, et al. 1998. 2,3,7,8-Tetrachlorodibenzo-p-dioxin plasma levels in Seveso 20 years after the accident. Environ Health Perspect 106:273-277.

Landi MT, Needham LL, Lucier G, Mocarelli P, Bertazzi PA, Caporaso N. 1997. Concentrations of dioxin 20 years after Seveso [Letter]. Lancet 349:1811.

Li CY, Sung FC. 1999. A review of the healthy worker effect in occupational epidemiology. Occup Med 49:225-229.

Lovik M, Johansen HR, Gaarder PI, Becher G, Aaberge IS, Gdynia W, et al. 1996. Halogenated organic compounds and the human immune system: preliminary report on a study in hobby fishermen. Arch Toxicol 18(suppl):15-20.

Marth E, Sixl W, Bencko V, Medwed M, Lapajne S, Voncina E, et al. 1995. People on the garbage dumps of Cairo: a toxicological in vivo model? Cent Eur J Public Health 3:154-157.

Michalek JE, Ketchum NS, Check IJ. 1995. Serum dioxin and immunologic response in veterans of Operation Ranch Hand. Am J Epidemiol 149:1038-1046.

Nagayama J, Tsuji H, Iida T, Hirakawa H, Matsueda T, Ohki M. 2001. Effects of contamination level of dioxins and related chemicals on thyroid hormone and immune response systems in patients with "Yusho". Chemosphere 43:1005-1010.

Neubert R, Maskow L, Triebig G, Broding HC, Jacob-Muller U, Helge H, et al. 2000. Chlorinated dibenzo-p-dioxins and dibenzofurans and the human immune system: 3. Plasma immunoglobulins and cytokines of workers with quantified moderately-increased body burdens. Life Sci 66:2123-2142.

Nohara K, Fujimaki H, Tsukumo S, Inouye K, Sone H, Tohyama C. 2002. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on T cell-derived cytokine production in ovalbumin (OVA)-immunized C57BI/6 mice. Toxicology 172:49-58.

Ott MG, Zober A, Germann C. 1994. Laboratory results for selected target organs in 138 individuals occupationally exposed to TCDD. Chemosphere 29:2423-2437.

Patterson DG Jr, Hampton L, Lapeza CR Jr, Belser WT, Green V, Alexander L, et al. 1987. High-resolution gas chromatographic/high-resolution mass spectrometric analysis of human serum on a whole-weight and lipid basis for 2,3,7,8-tetrachlorodibenzo-p-dioxin. Anal Chem 59:2000-2005.

Pocchiari F, Silano V, Zampieri A. 1979. Human health effects from accidental release of tetrachlorodibenzo-p-dioxin (TCDD) at Seveso, Italy. Ann NY Acad Sci 320-311-320.

Ravel R. 1995. Serum proteins. In: Clinical Laboratory Medicine. St. Louis: Mosby-Year Book, 342-368.

Rothman KJ, Greenland S. 1998. Prevention of confounding. In: Modern Epidemiology (Rothman KJ, Greenland S, eds). 2nd ed. Philadelphia: Lippincott-Raven, 143-145.

Sirchia GG. 1982. Exposure to TCDD: immunologic effects. In: Plans for Clinical and Epidemiologic Follow-up after Areawide Chemical Contamination (Dardanoni L, Miller RW, eds). Washington, DC: National Academy Press, 234-266.

Sulentic CE, Holsapple MP, Kaminski NE. 2000. Putative link between transcriptional regulation of IgM expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin and the aryl hydrocarbon receptor/dioxin-responsive enhancer signaling pathway. J Pharmacol Exp Ther 295:705-716.

Thomas L. 1990. Quantitative immunochemical plasma protein analysis by immunonephelometry and immunoturbidimetry. Lab Med 14:313-320.

Vorderstrasse BA, Steppan LB, Silverstone AE, Kerkvliet NI. 2001. Aryl hydrocarbon receptor-deficient mice generate normal immune responses to model antigens and are resistant to TCDD-induced immune suppression. Toxicol Appl Pharmacol 171:157-164.

Webb KB, Evans RG, Knutsen AP, Roodman ST, Roberts DW, Schramm WF, at al. 1989. Medical evaluation of subjects with known body levels of 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Toxicol Environ Health 28:183-193.

WHO-ECEH. 2000. Consultation on assessment of the health risk of dioxins; re-evaluation of the tolerable daily intake (TDI): executive summary. Food Addit Contam 17:223-240.

Ziegler FP. 1994. Cancer in the immunocompromised host. In: Basic and Clinical Immunology (Stites DP, Terr AI, Parslow TG, eds). 8th ed. Philadelphia: Lippincott-Raven, 578-587.

Zober A, Ott MG, Messerer P. 1994. Morbidity follow up study of BASF employees exposed to 2,3,7, 8-tetrachlorodibenzo-p-dioxin (TCDD) after a 1953 chemical reactor incident. Occup Environ Med 51:479-486.

Andrea Baccarelli, (1,2) Paolo Mocarelli, (3) Donald G. Patterson Jr., (4) Matteo Bonzini, (2) Angela C. Pesatori, (2) Neil Caporaso, (1) and Maria Teresa Landi (1)

(1) Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA; (2) Department of Occupational Health, University of Milan, Milan, Italy; (3) Department of Laboratory Medicine, University of Milan-Bicocca, Desio, Italy; (4) National Center for Environmental Health, Centers for Disease Control, Atlanta, Georgia, USA

Address correspondence to M.T. Landi, Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, EPS 7114, Bethesda, MD 20892-7236 USA. Telephone: [phone]. Fax: [phone]. E-mail: [e-mail]

We are grateful to the study participants and to A. Carobene and P.A. Bertazzi for their insightful comments.

This work was supported by the government of the Lombardy Region, with additional funding from the Italian Ministry of University and Scientific Research, and the Foundation "Lombardia per l'Ambiente."

Received 8 March 2002; accepted 8 May 2002.